inactivated poliovirus vaccine


Also found in: Dictionary, Thesaurus, Encyclopedia.

po·li·o·vi·rus vac·cines

1. inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine;
2. oral poliovirus vaccine (OPV), an aqueous suspension of live, attenuated strains of poliomyelitis virus (types 1, 2, and 3) given orally for active immunization against poliomyelitis.

inactivated poliovirus vaccine

, poliovirus vaccine, inactivated
An injectable vaccine made from three types of inactivated polioviruses. Developed by Jonas E. Salk, it was the first successful vaccine against poliomyelitis and is now the only polio vaccine administered in the U.S. Synonym: Salk vaccine

Infants should be given three doses, the first at 2 months of age, followed by two more doses at 8-week intervals. A fourth dose should be given at age 18 months unless poliomyelitis is endemic in the area, in which case the fourth dose is given 6 to 12 months after the third. Additional doses are recommended prior to school entry and then every 5 years until age 18.

See also: vaccine
References in periodicals archive ?
Sabin-IPV is an inactivated poliovirus vaccine derived from attenuated strains, and its safety and efficacy are expected to be comparable to the inactivated polio vaccines derived from virulent strains, which are commonly used outside Japan.
(10.) Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries.
MMR, inactivated poliovirus vaccine, and varicella vaccine are administered SQ.
Starting in 2015, injectable trivalent inactivated poliovirus vaccine (IPV) was introduced into routine immunization schedules in OPV-using countries, generally at 14 weeks of age.
The children also received all other childhood recommended vaccines (DTaP, hepatitis B vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b vaccine, and meningococcal group C conjugate vaccine).
In this single-blind, Phase II study, 609 infants were randomized 1:1 to receive either Hib-MenCY-TT or licensed Hib vaccine at 2, 4, and 6 months concomitantly with DTaP-Hep B-IPV (Pediarix[R] Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B [Recombinant] and Inactivated Poliovirus Vaccine Combined) and pneumococcal 7-valent conjugate vaccine (Prevnar[R] Pneumococcal 7-valent Conjugate Vaccine Diphtheria CRM Protein).
VAPP denotes vaccine-associated paralytic poliomyelitis; DTaP-HIB, diptheria tetanus acellular pertussis-Haemophilus influenzae type B vaccine; IPV, inactivated poliovirus vaccine.
Vaccination options for these activities include the use of monovalent oral poliovirus vaccine type 2 (mOPV2) and/or inactivated poliovirus vaccine (IPV) for polio vaccination campaigns.
6 Two poliovirus vaccines are currently licensed in the U.S.: inactivated poliovirus vaccine (IPV) and oral poliovirus (OPV).
To minimize the risks for paralytic poliomyelitis associated with PV2, vaccination with the inactivated poliovirus vaccine (IPV) will be needed for the foreseeable future (6).